Supplemental Material related to "Phase 2 randomized controlled trial of serlopitant, a neurokinin 1 receptor antagonist for chronic pruritus in epidermolysis bullosa. U Okata-Karigane et al., 2022"

Supplemental Material related to "Phase 2 randomized controlled trial of serlopitant, a neurokinin 1 receptor antagonist for chronic pruritus in epidermolysis bullosa. U Okata-Karigane et al., 2022" Supplemental Figure S1. Participant flow in the double-blind phase and open-label extension study. Supplemental Figure S2. The change in the Static Participant Assessment of Itch (SPAI) at month 2. Supplemental Figure S3. Monthly NRS change in the open-label extension study. Supplemental Table S1. Detailed inclusion and exclusion criteria. Supplemental Table S2. Detailed masking and blinding. Supplemental Table S3. A linear mixed model analysis for relative weekly NRS change. Supplemental Table S4. Patient Global Impression of Change at month 2. Supplemental Table S5. Minimal Clinically Important Difference (MCID) for the Average Itch NRS based on PGIC. Supplemental Table S6. Changes in quality of life or pruritus-related questionnaires at month 2 from baseline. Supplemental Table S7. Detailed open-label extension.